Innovent Biologics reports strong Q3 2025 revenue growth

Innovent Biologics, Inc. reported total product revenue exceeding RMB3.3 bn for the third quarter of 2025, marking approximately 40% year-on-year growth. This robust performance was attributed to the dual expansion of its oncology and general biomedicine product portfolios. Key oncology products, including TYVYT (sintilimab injection), sustained growth, complemented by increasing contributions from newly-launched oncology offerings.

The general biomedicine franchise also saw rapid revenue expansion and unlocked potential, with mazdutide, SINTBILO (tafolecimab injection), and SYCUME (teprotumumab N01 injection) experiencing accelerated uptake due to enhanced market access and marketing strategies. Furthermore, mazdutide received approval for a second indication—type 2 diabetes—by China’s National Medical Products Administration, broadening its market reach.

Innovent is committed to sustainable growth and global innovation, boasting 16 approved products, two new drug applications under review, four assets in Phase III or pivotal clinical trials, and 15 molecules in early clinical stages. The company considers 2025 a pivotal year as it embarks on a new era of sustainable growth and global innovation.